Journal article
Use of alkylating chemotherapy in high-grade neuroendocrine tumours: Evaluation of real-world data.
Abstract
78
Background: High-grade neuroendocrine tumours (NETs) are believed to have activity to certain alkylating agents, although data are scant. These regimens include streptozotocin (STZ) (used in combination with doxorubicin or 5-fluorouracil) and dacarbazine (DTIC). Current series report variable responses between 6 – 69%. Our objective was to evaluate our real world data to better understand treatment decision-making and …
Authors
Sathiyapalan A; Sanatani MS; Welch S; Kocha WI; Richter S
Journal
Journal of Clinical Oncology, Vol. 34, No. 7_suppl, pp. 78–78
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
March 1, 2016
DOI
10.1200/jco.2016.34.7_suppl.78
ISSN
0732-183X